CN113302204A - 用于治疗癌症的抗tigit抗体的给药方案 - Google Patents

用于治疗癌症的抗tigit抗体的给药方案 Download PDF

Info

Publication number
CN113302204A
CN113302204A CN201980087763.5A CN201980087763A CN113302204A CN 113302204 A CN113302204 A CN 113302204A CN 201980087763 A CN201980087763 A CN 201980087763A CN 113302204 A CN113302204 A CN 113302204A
Authority
CN
China
Prior art keywords
antibody
light chain
heavy chain
seq
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980087763.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·蔡
E·K·查尔塔什
J·A·希利
M·拉拉
T·R·李
K·玛亚瓦拉
R·A·普雷多尤
S·M·G·威廉姆斯
Z·曾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme BV
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of CN113302204A publication Critical patent/CN113302204A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN201980087763.5A 2018-11-05 2019-11-04 用于治疗癌症的抗tigit抗体的给药方案 Pending CN113302204A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755805P 2018-11-05 2018-11-05
US62/755,805 2018-11-05
PCT/US2019/059581 WO2020096915A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-tigit antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
CN113302204A true CN113302204A (zh) 2021-08-24

Family

ID=70611082

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980087763.5A Pending CN113302204A (zh) 2018-11-05 2019-11-04 用于治疗癌症的抗tigit抗体的给药方案

Country Status (10)

Country Link
US (1) US20210403557A1 (cg-RX-API-DMAC7.html)
EP (1) EP3877418A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022512851A (cg-RX-API-DMAC7.html)
KR (1) KR20210091209A (cg-RX-API-DMAC7.html)
CN (1) CN113302204A (cg-RX-API-DMAC7.html)
AU (1) AU2019375409A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008582A8 (cg-RX-API-DMAC7.html)
CA (1) CA3118964A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005236A (cg-RX-API-DMAC7.html)
WO (1) WO2020096915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2021257124A1 (en) * 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
EP4219553A4 (en) * 2020-09-22 2024-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-TIGIT ANTIBODIES AND DUAL ANTIBODIES AND THEIR APPLICATION
JP2024532744A (ja) * 2021-08-10 2024-09-10 メルク・シャープ・アンド・ドーム・エルエルシー T1gitアンタゴニスト、pd-1アンタゴニスト、及び(1又は複数の)化学療法剤を含む治療的組合せ
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025128499A1 (en) * 2023-12-12 2025-06-19 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN118671353A (zh) * 2024-05-30 2024-09-20 中国人民解放军总医院第一医学中心 用于ais诊断的生物标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106068275A (zh) * 2014-01-23 2016-11-02 瑞泽恩制药公司 抗pd‑1的人抗体
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689369A1 (en) * 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
HRP20201334T1 (hr) * 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
SG10202007764TA (en) * 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
CA3025391A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US20210363243A1 (en) * 2018-02-01 2021-11-25 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106068275A (zh) * 2014-01-23 2016-11-02 瑞泽恩制药公司 抗pd‑1的人抗体
CN107148430A (zh) * 2014-08-19 2017-09-08 默沙东公司 抗tigit抗体

Also Published As

Publication number Publication date
KR20210091209A (ko) 2021-07-21
MX2021005236A (es) 2021-06-18
JP2022512851A (ja) 2022-02-07
EP3877418A4 (en) 2022-08-17
WO2020096915A1 (en) 2020-05-14
AU2019375409A1 (en) 2021-05-27
BR112021008582A2 (pt) 2021-08-10
JP2025004212A (ja) 2025-01-14
BR112021008582A8 (pt) 2023-02-07
US20210403557A1 (en) 2021-12-30
EP3877418A1 (en) 2021-09-15
CA3118964A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
CN105451770B (zh) 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
JP6783312B2 (ja) がんを処置するためのox40アゴニストおよび4−1bbアゴニストモノクローナル抗体の組み合わせ
JP2023039448A (ja) がんを治療するための、pd-1アンタゴニスト及びvegfr/fgfr/retチロシンキナーゼ阻害剤の組合せ
CN107810013B (zh) 用于治疗癌症的pd-1拮抗剂和艾立布林的组合
US20210403557A1 (en) Dosing regimen of anti-tigit antibody for treatment of cancer
JP7470105B2 (ja) 非マイクロサテライト高不安定性/ミスマッチ修復の良好な結腸直腸がんを処置するためのpd-1アンタゴニストおよびlag3アンタゴニストの組み合わせ
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
TW201615212A (zh) 用於治療癌症之pd-1拮抗劑及vegfr抑制劑之組合
EP4155319A1 (en) 4-1bb binding protein and application thereof
CN116710132A (zh) 抗ilt4抗体或其与抗pd-1抗体的组合用于治疗癌症的给药方案
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN117794569A (zh) 使用抗ctla4抗体治疗癌症的方法
RU2833669C2 (ru) Режим введения антитела к tigit для лечения рака
KR20230087451A (ko) 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
WO2025128499A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
WO2025054110A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with cancer before and/or after surgery
HK40109251A (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
HK1228930A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220922

Address after: new jersey

Applicant after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Applicant before: MERCK SHARP & DOHME Corp.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210824

WD01 Invention patent application deemed withdrawn after publication